Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway ; volume:19 ; number:1 ; day:2 ; month:5 ; year:2019 ; pages:1-15 ; date:12.2019
Cancer cell international ; 19, Heft 1 (2.5.2019), 1-15, 12.2019
- Classification
-
Medizin, Gesundheit
- Creator
-
Song, Yong-An
Ma, Ting
Zhang, Xue-Yan
Cheng, Xiang-Song
Olajuyin, Ayobami-Matthew
Sun, Zhi-Fu
Zhang, Xiao-Ju
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-019-0836-8
- URN
-
urn:nbn:de:101:1-2019052122184702748397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Song, Yong-An
- Ma, Ting
- Zhang, Xue-Yan
- Cheng, Xiang-Song
- Olajuyin, Ayobami-Matthew
- Sun, Zhi-Fu
- Zhang, Xiao-Ju
- SpringerLink (Online service)
Other Objects (12)
Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells
Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3+CD11b+ cells
RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas
Apatinib monotherapy for early non-small cell lung cancer: a case report
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells
Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3+CD11b+ cells
RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas
Apatinib monotherapy for early non-small cell lung cancer: a case report
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells
Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3+CD11b+ cells
RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas
Apatinib monotherapy for early non-small cell lung cancer: a case report
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation